Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?"
1 Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Piet Ost, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Katrien Vandecasteele, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Gent, Belgium; Geert De Kerf, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium; Michaël Claessens, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Peter Vermeulen, MD, PhD, Translational Cancer Research Unit (TCRU)-GZA Ziekenhuizen, Wilrijk, Antwerp, Belgium; Luc Dirix, MD, PhD, Department of Medical Oncology, GZA Ziekenhuizen Sint-Augustinus, Wilrijk, Antwerp, Belgium; Yolande Lievens, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium, Department of Radiation Oncology, University Hospital Ghent, Ghent, Belgium; Dirk Verellen, PhD, MSc, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; and Piet Dirix, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium.